• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.970 +0.100 (+2.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
April 15, 2026
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
March 23, 2026
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
March 05, 2026
In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
Via MarketMinute
Topics Intellectual Property Lawsuit
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
January 16, 2026
Via Stocktwits
Topics Intellectual Property
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
March 04, 2026
The news is likely to come as a relief to many investors, Citi told investors in a research note. 
Via Stocktwits
Topics Intellectual Property
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
March 03, 2026
The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines. 
Via Stocktwits
Topics Intellectual Property
News headline image
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
March 03, 2026
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
March 03, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
January 16, 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's pre-market session. ↗
January 16, 2026
Via Chartmill
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
January 14, 2026
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
January 12, 2026
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
January 09, 2026
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
October 21, 2025
Arbutus Biopharma (ABUS) shows strong technical health and high-growth momentum, with surging sales and earnings, positioning it for potential gains. 
Via Chartmill
News headline image
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
October 07, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus (ABUS) Q2 Revenue Surges 529% ↗
August 06, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
June 25, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 07, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
March 27, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
March 03, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Provides 2025 Corporate and Financial Update
January 13, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
December 03, 2024
From Whitefort Capital Management, LP
Via Business Wire
News headline image
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
November 26, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
November 20, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap